Table 2. Fbw7 mutation and homozygous deletion frequency in selected cancers.
| Tumor Type | No. samples | Arginine hotspot mutations | Nonsense mutations | Other missense mutations | All point mutations | Arginine hotspot mutations/total point mutations | Homozygous deletions (%) |
|---|---|---|---|---|---|---|---|
| Uterine Carcinosarcoma | 56 | 23% | 4% | 14% | 39% | 59% | 0% |
| Colon and rectal adenocarcinoma | 212 | 8% | 3% | 6% | 17% | 49% | 0% |
| Uterine corpus endometrial carcinoma | 240 | 6% | 3% | 8% | 16% | 37% | 0% |
| Stomach adenocarcinoma | 219 | 5% | 2% | 2% | 9% | 59% | <1% |
| Urothelial bladder carcinoma | 127 | 3% | 5% | 4% | 9% | 33% | 2% |
| Lung squamous cell carcinoma | 178 | 2% | 2% | 2% | 6% | 36% | <1% |
| Head and neck squamous cell carcinoma | 302 | 2% | <1% | 3% | 5% | 33% | 1% |
| Cutaneous melanoma | 262 | <1% | 1% | 3% | 4% | 9% | <1% |
| Breast cancer | 962 | <1% | <1% | 1% | 2% | 20% | <1% |
| Cervical squamous adenocarcinoma | 36 | 0% | 3% | 3% | 6% | 0% | 0% |
| Lung adenocarcinoma | 230 | 0% | 1% | <1% | 2% | 0% | 0% |
| Glioblastoma multiforme | 281 | 0% | <1% | 0% | <1% | 0% | <1% |
Mutation and copy number alteration data were derived from analyses of TCGA data using cBioPortal (Cerami et al., 2012; Gao et al., 2013).